175 related articles for article (PubMed ID: 21138868)
1. Combination therapy targeting both tumor-initiating and differentiated cell populations in prostate carcinoma.
Dubrovska A; Elliott J; Salamone RJ; Kim S; Aimone LJ; Walker JR; Watson J; Sauveur-Michel M; Garcia-Echeverria C; Cho CY; Reddy VA; Schultz PG
Clin Cancer Res; 2010 Dec; 16(23):5692-702. PubMed ID: 21138868
[TBL] [Abstract][Full Text] [Related]
2. Dual PI3K/mTOR inhibitor NVP-BEZ235 sensitizes docetaxel in castration resistant prostate cancer.
Yasumizu Y; Miyajima A; Kosaka T; Miyazaki Y; Kikuchi E; Oya M
J Urol; 2014 Jan; 191(1):227-34. PubMed ID: 23954373
[TBL] [Abstract][Full Text] [Related]
3. The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations.
Dubrovska A; Kim S; Salamone RJ; Walker JR; Maira SM; García-Echeverría C; Schultz PG; Reddy VA
Proc Natl Acad Sci U S A; 2009 Jan; 106(1):268-73. PubMed ID: 19116269
[TBL] [Abstract][Full Text] [Related]
4. CD133+CD44+ population efficiently enriches colon cancer initiating cells.
Haraguchi N; Ohkuma M; Sakashita H; Matsuzaki S; Tanaka F; Mimori K; Kamohara Y; Inoue H; Mori M
Ann Surg Oncol; 2008 Oct; 15(10):2927-33. PubMed ID: 18663533
[TBL] [Abstract][Full Text] [Related]
5. Coencapsulation of epirubicin and metformin in PEGylated liposomes inhibits the recurrence of murine sarcoma S180 existing CD133+ cancer stem-like cells.
Yang Q; Zhang T; Wang C; Jiao J; Li J; Deng Y
Eur J Pharm Biopharm; 2014 Nov; 88(3):737-45. PubMed ID: 25460146
[TBL] [Abstract][Full Text] [Related]
6. Cells with characteristics of cancer stem/progenitor cells express the CD133 antigen in human endometrial tumors.
Rutella S; Bonanno G; Procoli A; Mariotti A; Corallo M; Prisco MG; Eramo A; Napoletano C; Gallo D; Perillo A; Nuti M; Pierelli L; Testa U; Scambia G; Ferrandina G
Clin Cancer Res; 2009 Jul; 15(13):4299-311. PubMed ID: 19509143
[TBL] [Abstract][Full Text] [Related]
7. Dual blockade of PI3K/AKT/mTOR (NVP-BEZ235) and Ras/Raf/MEK (AZD6244) pathways synergistically inhibit growth of primary endometrioid endometrial carcinoma cultures, whereas NVP-BEZ235 reduces tumor growth in the corresponding xenograft models.
Schrauwen S; Depreeuw J; Coenegrachts L; Hermans E; Lambrechts D; Amant F
Gynecol Oncol; 2015 Jul; 138(1):165-73. PubMed ID: 25933683
[TBL] [Abstract][Full Text] [Related]
8. CD133 expression defines a tumor initiating cell population in primary human ovarian cancer.
Curley MD; Therrien VA; Cummings CL; Sergent PA; Koulouris CR; Friel AM; Roberts DJ; Seiden MV; Scadden DT; Rueda BR; Foster R
Stem Cells; 2009 Dec; 27(12):2875-83. PubMed ID: 19816957
[TBL] [Abstract][Full Text] [Related]
9. Activation of AR sensitizes breast carcinomas to NVP-BEZ235's therapeutic effect mediated by PTEN and KLLN upregulation.
Wang Y; Yu Q; He X; Romigh T; Altemus J; Eng C
Mol Cancer Ther; 2014 Feb; 13(2):517-27. PubMed ID: 24356815
[TBL] [Abstract][Full Text] [Related]
10. Pristimerin Inhibits Prostate Cancer Bone Metastasis by Targeting PC-3 Stem Cell Characteristics and VEGF-Induced Vasculogenesis of BM-EPCs.
Huang S; He P; Peng X; Li J; Xu D; Tang Y
Cell Physiol Biochem; 2015; 37(1):253-68. PubMed ID: 26302893
[TBL] [Abstract][Full Text] [Related]
11. Cancer stem-like cells in human prostate carcinoma cells DU145: the seeds of the cell line?
Wei C; Guomin W; Yujun L; Ruizhe Q
Cancer Biol Ther; 2007 May; 6(5):763-8. PubMed ID: 17592251
[TBL] [Abstract][Full Text] [Related]
12. Co-delivery of platinum drug and siNotch1 with micelleplex for enhanced hepatocellular carcinoma therapy.
Shen S; Sun CY; Du XJ; Li HJ; Liu Y; Xia JX; Zhu YH; Wang J
Biomaterials; 2015 Nov; 70():71-83. PubMed ID: 26302232
[TBL] [Abstract][Full Text] [Related]
13. BMI-1 Targeting Interferes with Patient-Derived Tumor-Initiating Cell Survival and Tumor Growth in Prostate Cancer.
Bansal N; Bartucci M; Yusuff S; Davis S; Flaherty K; Huselid E; Patrizii M; Jones D; Cao L; Sydorenko N; Moon YC; Zhong H; Medina DJ; Kerrigan J; Stein MN; Kim IY; Davis TW; DiPaola RS; Bertino JR; Sabaawy HE
Clin Cancer Res; 2016 Dec; 22(24):6176-6191. PubMed ID: 27307599
[TBL] [Abstract][Full Text] [Related]
14. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.
Serra V; Markman B; Scaltriti M; Eichhorn PJ; Valero V; Guzman M; Botero ML; Llonch E; Atzori F; Di Cosimo S; Maira M; Garcia-Echeverria C; Parra JL; Arribas J; Baselga J
Cancer Res; 2008 Oct; 68(19):8022-30. PubMed ID: 18829560
[TBL] [Abstract][Full Text] [Related]
15. Silibinin suppresses the maintenance of colorectal cancer stem-like cells by inhibiting PP2A/AKT/mTOR pathways.
Wang JY; Chang CC; Chiang CC; Chen WM; Hung SC
J Cell Biochem; 2012 May; 113(5):1733-43. PubMed ID: 22213051
[TBL] [Abstract][Full Text] [Related]
16. Expression analysis of putative stem cell markers in human benign and malignant prostate.
Ugolkov AV; Eisengart LJ; Luan C; Yang XJ
Prostate; 2011 Jan; 71(1):18-25. PubMed ID: 20583131
[TBL] [Abstract][Full Text] [Related]
17. Bone morphogenetic protein 4 induces differentiation of colorectal cancer stem cells and increases their response to chemotherapy in mice.
Lombardo Y; Scopelliti A; Cammareri P; Todaro M; Iovino F; Ricci-Vitiani L; Gulotta G; Dieli F; de Maria R; Stassi G
Gastroenterology; 2011 Jan; 140(1):297-309. PubMed ID: 20951698
[TBL] [Abstract][Full Text] [Related]
18. Phenotypic subpopulations of metastatic colon cancer stem cells: genomic analysis.
Botchkina IL; Rowehl RA; Rivadeneira DE; Karpeh MS; Crawford H; Dufour A; Ju J; Wang Y; Leyfman Y; Botchkina GI
Cancer Genomics Proteomics; 2009; 6(1):19-29. PubMed ID: 19451087
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA-7 inhibits the stemness of prostate cancer stem-like cells and tumorigenesis by repressing KLF4/PI3K/Akt/p21 pathway.
Chang YL; Zhou PJ; Wei L; Li W; Ji Z; Fang YX; Gao WQ
Oncotarget; 2015 Sep; 6(27):24017-31. PubMed ID: 26172296
[TBL] [Abstract][Full Text] [Related]
20. Specific elimination of CD133+ tumor cells with targeted oncolytic measles virus.
Bach P; Abel T; Hoffmann C; Gal Z; Braun G; Voelker I; Ball CR; Johnston IC; Lauer UM; Herold-Mende C; Mühlebach MD; Glimm H; Buchholz CJ
Cancer Res; 2013 Jan; 73(2):865-74. PubMed ID: 23293278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
